Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Camlipixant by GSK for Chronic Cough: Likelihood of Approval
Camlipixant is under clinical development by GSK and currently in Phase III for Chronic Cough. According to GlobalData, Phase III...
Camlipixant by GSK for Chronic Cough: Likelihood of Approval
Camlipixant is under clinical development by GSK and currently in Phase III for Chronic Cough. According to GlobalData, Phase III...
Risk adjusted net present value: What is the current valuation of GSK's Camlipixant?
Camlipixant is a small molecule commercialized by GSK, with a leading Phase III program in Chronic Cough. According to Globaldata,...